Potential biomarker screening for dilated cardiomyopathy using plasma-derived exosome metabolomics

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400079896

Enrollment

Unknown

Registered

2024-01-15

Start date

2024-02-01

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dilated cardiomyopathy

Interventions

Dilated cardiomyopathy with heart failure:N/A

Healthy:N/A

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Age >18 years 2. Left ventricular end-diastolic internal diameter (LVEDd) >5.0cm (female), (LVEDd) >5.5cm (male) 3. Left ventricular ejection fraction (LVEF) 450 pg/mL in patients under 50 years old; NT-proBNP >900 pg/mL in patients 50-75 years old; NT-proBNP should be >1800 pg/m in patients over 75 years old; in renal insufficiency (glomerular filtration rate 1200ngL

Exclusion criteria

Exclusion criteria: 1. Alcoholic cardiomyopathy, perinatal cardiomyopathy, tachycardia cardiomyopathy and other acquired DCM 2. autoimmune diseases, metabolic endocrine diseases, nutritional diseases and other organ diseases secondary to DCM 3. other types of heart disease: ischemic heart disease, hypertensive heart disease, valvular heart disease, congenital heart disease, pulmonary heart disease 4. Acute coronary syndrome 5. Acute pulmonary embolism 6. Acute aortic coarctation 7. malignant tumors and autoimmune diseases

Design outcomes

Primary

Measure	Time frame
General clinical data;Exosome;Metabolites data;	—

Secondary

Measure	Time frame
Receiver operating characteristic curve;	—

Countries

China

Contacts

Public ContactFanqi Meng

Cardiovascular Hospital of Xiamen University, Xiamen, Fujian Province

mengfanqi19831001@163.com+86 159 5923 2882

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026